MedTrace Logo

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

NCT05054140 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2024-04-29

No results posted yet for this study

Summary

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

Conditions

Interventions

DRUG

IMU-838

IMU-838 tablets

DRUG

Placebo matching IMU-838

Placebo matching IMU-838 tablets

Sponsors & Collaborators

  • Immunic AG

    lead INDUSTRY

Principal Investigators

  • Robert J. Fox, MD · Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2025-01-07
Completion
2025-01-07
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Moldova
  • Netherlands
  • North Macedonia
  • Poland
  • Romania
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054140 on ClinicalTrials.gov